Interestingly, FOXK2 expression is correlated with reduced disease-free survival in breast cancer patients, consistently with the in vitro data supporting the hypothesis that constitutively high expression levels of nuclear FOXK2 are closely associated with poor clinical outcome and drug resistance [43]. The gene discussed is FOXK2; the disease is breast carcinoma.